ASCO-2016: PRE CONFERENCE INSIGHTS

The American Society of Clinical Oncology (ASCO) annual meeting happens each June in Chicago. It is one of the premier meetings each year where oncologists, scientists and advocates gather to hear the latest clinical trial data in oncology, including focused sessions on GI cancers such…

Read Full Post

Reprogramming a Tumor for Death

In previous columns of The Currently Incurable Scientist, we’ve gone over a number of different types of colorectal cancer (CRC) experimental therapies – from targeted agents to various flavors of immunotherapies. In this installment, I want to introduce you to yet another area of intense…

Read Full Post

Ramucirumab – A New Treatment Option

The FDA approved the use of the drug ramucirumab (brand name Cyramza®) on April 24, 2015 for patients with metastatic colorectal cancer in combination with FOLFIRI. Ramucirumab with FOLFIRI is now approved for patients whose cancer has progressed during or after treatment with first line…

Read Full Post

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to available treatments. FDA’s action was…

Read Full Post

Avastin with XELIRI or FOLFIRI: Is There Any Difference?

When Avastin is added to the combination of Xeloda and irinotecan as an initial treatment for advanced colorectal cancer, the treatment is equally effective as Avastin with FOLFIRI. But side effects are more difficult. After a randomized clinical trial comparing Avastin with XELIRI (Xeloda, irinotecan)…

Read Full Post